Alternatives to Carboplatin If You Can't Fill Your Prescription

Carboplatin is one of the most widely used chemotherapy drugs in oncology, and its ongoing shortage since April 2023 has created a serious challenge for cancer patients and their care teams. If your oncology center cannot obtain carboplatin in time for your scheduled treatment, your oncologist will need to evaluate alternatives on a case-by-case basis. This article explains what options exist, according to major oncology societies, and what factors determine which alternative might be right for each cancer type.

Important: Only Your Oncologist Can Choose an Alternative

ASHP has stated clearly that "no single agent can be substituted for carboplatin" — meaning there is no universal direct swap. Every alternative involves clinical tradeoffs in efficacy, toxicity, or both. The right choice depends on your cancer type, disease stage, treatment goal (curative vs. palliative), kidney function, and prior treatment history. Always work with your oncologist before making any change to your chemotherapy regimen.

Cisplatin: The Closest Platinum Alternative

Cisplatin is the first-generation platinum agent and the most similar drug to carboplatin in terms of mechanism and tumor coverage. For many cancer types — including ovarian cancer, NSCLC, and cervical cancer — cisplatin can be substituted when carboplatin is unavailable, provided the patient can tolerate its more significant toxicity profile.

Key differences to consider:

Cisplatin causes significantly more nausea and vomiting than carboplatin

Cisplatin requires extensive IV hydration and is typically administered over many hours, often requiring hospitalization or a long infusion day

Cisplatin carries a higher risk of kidney damage (nephrotoxicity) and hearing loss (ototoxicity)

Patients with pre-existing kidney impairment, hearing loss, or advanced age may not be candidates for cisplatin

Oxaliplatin: A Third-Generation Option for Some Cancers

Oxaliplatin is primarily used in colorectal and GI cancers, but oncologists have also used it as a third-line substitution in gynecologic cancers when both carboplatin and cisplatin are unavailable or the patient has developed hypersensitivity to carboplatin. The Society of Gynecologic Oncology has noted that oxaliplatin at 130 mg/m² every 21 days may be considered as a substitution option in multi-agent regimens.

Oxaliplatin has a different side effect profile, with peripheral neuropathy (nerve damage, often causing cold sensitivity) being its main toxicity. It causes less kidney damage than cisplatin.

Non-Platinum Alternatives by Cancer Type

In some settings, entirely non-platinum regimens may be considered. ASCO's Drug Shortages Advisory Group has published disease-specific guidance:

Ovarian cancer: ASCO recommends reserving carboplatin for curative-intent regimens. For recurrent, platinum-resistant ovarian cancer, options such as pegylated liposomal doxorubicin (Doxil), topotecan, or gemcitabine may be appropriate.

NSCLC: For patients where carboplatin-based doublet chemotherapy is being considered, substituting cisplatin in patients who can tolerate it, or considering immunotherapy-only regimens where indicated (e.g., high PD-L1 expressors), may be appropriate alternatives.

Cervical cancer: For recurrent disease, when neither cisplatin nor carboplatin is available, topotecan plus paclitaxel plus bevacizumab has been identified as a preferred non-platinum-based regimen. Pembrolizumab may also be added for PD-L1 positive tumors.

SCLC: Carboplatin plus etoposide is the standard regimen. Cisplatin plus etoposide may be substituted. In extensive-stage disease, checkpoint inhibitor combinations have been added to these backbones.

Carboplatin Hypersensitivity: When You Need an Alternative Long-Term

Separate from the shortage issue, some patients develop hypersensitivity reactions to carboplatin — typically after 6–8 cycles. In this case, desensitization protocols can sometimes allow carboplatin to continue, but when that is not possible, cisplatin or oxaliplatin become the main platinum alternatives depending on cancer type and tolerability.

The Bottom Line: Exhaust All Supply Options First

Before switching regimens, it is worth exhausting every option to source carboplatin. medfinder can call pharmacies and infusion centers near you to check which ones have carboplatin in stock. Avoiding unnecessary regimen changes is always preferable when it is possible to source the original drug.

See our guide on how to find carboplatin in stock near you for practical steps to locate supply before your next infusion.